CN Patent

CN101223169A — 吡咯并[2,3-b]吡啶衍生物蛋白激酶抑制剂

Assigned to Plexxikon Inc · Expires 2008-07-16 · 18y expired

What this patent protects

本文提供了对受体蛋白酪氨酸激酶c－kit和c－fms具有活性的化合物。也提供了用于治疗c－kit介导的疾病或病症和c－fms介导的疾病或病症的组合物，和它们的应用方法。

USPTO Abstract

本文提供了对受体蛋白酪氨酸激酶c－kit和c－fms具有活性的化合物。也提供了用于治疗c－kit介导的疾病或病症和c－fms介导的疾病或病症的组合物，和它们的应用方法。

Drugs covered by this patent

pexidartinib-hydrochloride (PEXIDARTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN101223169A
Jurisdiction: CN
Classification: —
Expires: 2008-07-16
Drug substance claim: No
Drug product claim: No
Assignee: Plexxikon Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.